CD274 and neoplasm: Consistent with expectation, the OS in the population treated with pembrolizumab as monotherapy vs. EXTREME regimen was superior in neoplasms with high PD-L1 expression: patients with combined positive score (CPS) ≥ 20 had a median OS of 14.9 months vs. 10.8 months (HR = 0.61; CI, 0.46 to 0.81), while patients with CPS ≥ 1 had a median OS of 12.3 months vs. 10.4 months (HR = 0.71; CI, 0.61 to 0.89).